BioRestorative Therapies (BRTX) announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2M of its outstanding common stock through June 16, 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX:
- Promising Outlook for BioRestorative Therapies: Buy Rating Supported by Positive BRTX-100 Data and FDA Fast Track Designation
- BioRestorative Reports Promising Phase 2 Trial Results
- BioRestorative Therapies reports preliminary data from Phase 2 trial of BRTX-100
- BioRestorative Therapies appoints Sandy Lipkins for business development
- Positive Outlook for BioRestorative Therapies: Advancements in Clinical Trials and Financial Stability Drive Buy Rating